Stock slumps for Tel Aviv's Galmed fol­low­ing PhI­Ia NAFLD flop

The stock price is cra­ter­ing for thin­ly-trad­ed Tel Aviv com­pa­ny Galmed Phar­ma­ceu­ti­cals $GLMD, which just an­nounced a Phase IIa let­down of its non-al­co­holic fat­ty liv­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER